drugset / Trial / NCT00048412
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase 1/2
Completed
40 enrolled
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine · collabThe Methodist Hospital Research Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
1. To assess the treatment related mortality of allogeneic stem cell transplantation with non-myeloablative therapy incorporating the lymphodepleting MAb CAMPATH-1H, in patients with hematological diseases and renal cell carcinoma not eligible for conventional (myeloablative) therapy. 2. To assess the time to engraftment and incidence of graft failure in patients receiving this transplant regimen. 3. To assess the safety, pharmacokinetics and immunologic activity of CAMPATH-1H when used as part of a subablative conditioning regimen.
Timeline
- Start
- 2000-06
- Primary completion
- 2004-11-12
- Completion
- 2004-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | — |
| Background | FK50 | Unknown | — | — |
| Background | Fludarabine | Small molecule | — | — |